Clinical Trial Update: Comparison of Abacavir Following Once-Daily And Twice-Daily Administration In HIV Infected Subjects [Phase 1]

View source ↗

Summary

This Phase 1 trial compares once-daily and twice-daily dosing of abacavir in HIV-infected adults, assessing safety, tolerability, and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Ziagen (Abacavir)

Snippet

Sponsor: GlaxoSmithKline | Conditions: HIV Infection | Phase 1 | Status: COMPLETED